Anidulafungin: An evidence-based review of its use in invasive fungal infections

Core Evidence

Volumn 2, Issue 4, 2008, Pages 241-249

  Davis, Susan L ^a   Vazquez, Jose A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anidulafungin; Candidemia; Candidiasis; Echinocandins; Evidence; Review; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLOSPORIN; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; METRONIDAZOLE; MICAFUNGIN; NEVIRAPINE; POSACONAZOLE; RIFAMPICIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; CANDIDA ENDOCARDITIS; CANDIDEMIA; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG COST; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PREFERENCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; DYSPNEA; EARLY INTERVENTION; ESOPHAGUS CANDIDIASIS; EVIDENCE BASED MEDICINE; FLUSHING; FUNGICIDAL ACTIVITY; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOKALEMIA; HYPOTENSION; INJECTION SITE REACTION; INVASIVE CANDIDIASIS; LIVER DYSFUNCTION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; OROPHARYNX CANDIDIASIS; PRACTICE GUIDELINE; REVIEW; SEIZURE; SIDE EFFECT; STEADY STATE; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT;

EID: 54749115204     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother. 2002;46:451-457.
2. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother. 2006;50:2058-2063.
3. Benjamin DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632-638.
4. Brown GL, White RJ, Turik M. Phase II, randomized, open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, Sept 17-20, 2000. Abstract 1106.
5. Chavez M, Bernal S, Valverde A, Gutierrez MJ, Quindós G, Martin Mazuelos E. In vitro activity of voriconazole (UK-1 09,496), LY 303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemnother. 1999;44:697-700.
6. Chen A, Buhari M, Boikov D, et al. The complex epidemiology of Candida colonization in a tertiary care burn unit. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December 16-19, 2005. Abstract M-987.
7. Clemons KV, Stevens DA. Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them? Med Mycol. 2006;44:119-126.
8. Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother. 2006;50:3926-3928.
9. Cuenca-Estrella M, Mellado E, Díaz-Guerra TM, Monzón A, Rodriguez-Tudela JL. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole, and Amphotericin B. J Antimicrob Chemother. 2000;46:475-477.
10. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother. 2007;41:568-573
11. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998;37:173-180.
12. Denning DW. Echinocandins and pneumocandins-a new antifungal class with a novel mode of action. J Antimicrob Chemother. 1997;40:611-614.
13. Douglas CM, Foor F, Marrinan JA, et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci U S A. 1994;91:12907-12911.
14. Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol. 2001;(39 Suppl 1):55-66,
15. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44:590-598.
16. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol. 2005;45:1373-1382.
17. Dowell JA, Stogniew M, Krause D, Henkel T, Weston E. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol. 2005;45:227-233.
18. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36:2950-2956.
19. Garey KW, Rege M, Pal MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
20. Ghannoum MA, Chandra J, Mukherjee PK, Chen A, Buhari M, Vazquez J. Emergence of a multi-echinocandin resistant Candida parapsilosis. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, Dec 16-19, 2005. Late breaker.
21. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother. 2006;50:2522-2524.
22. Hurren JR, Davis SL, Vazquez JA. What is the risk of disulfiram-like reaction during anidulafungin and metronidazole administration? 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Illinois. Abstract K-2158.
23. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50:2892-2894.
24. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004a;39:770-775.
25. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia Antimicrob Agents Chemother, 2004b;48:2021-2024.
26. Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem. 2001;56:423-475.
27. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother. 2006;57:705-708.
28. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005;49:5058-5068.
29. Maligie MA, Selitrennikoff CR Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother. 2005;49:2851-2856.
30. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis. 1998;32:33-37.
31. Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacother. 2006;26:877-880.
32. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005;49:767-769.
33. Murdoch D, Plosker GL. Anidulafungin. Drugs. 2004;64:2249-2258.
34. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother. 2004;48:1912-1915.
35. Osherov N, May GS, Albert ND, Kontoyiannis DP. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2002;46:2462-2469.
36. Paderu R Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother. 2007;51:2253-2256
37. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
38. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49:3264-3273
39. Petraitiene R, Petraitis, V, Groll AH, et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother. 1999;43:2148-2155.
40. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005;43:5425-5427.
41. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbial. 2006;44:3533-3538.
42. Pfaller MA. Anidulafungin: an echinocandin antifungal. Expert Opin Investig Drugs. 2004;13:1183-1197.
43. Philip A, Odabasi Z, Rodriguez JR, et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother. 2005;49:3572-3574.
44. Prescribing Information, Cancidas®, available at: http://www.merck.com/product/usa/pi_Circulars/c/cancidas/ cancidas_pi.pdf
45. Prescribing Information, Eraxis®, available at: http://www.pfizer.comJpfizer/download/uspi_eraxis.pdf
46. Prescribing Information, Mycamine®, available at: http://www.astellas.us/docs/mycamine.pdf
47. Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther. 2004;2:499-508.
48. Reboli AC, Rotstein C, Pappas PG, et al; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472-2482.
49. Tawara S, Ikeda F, Maki K, at al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob, Agents Chemother. 2000;44:57-62.
50. Thye D, Kilfoil T, White R, Lasseter KC. Anidulafungin: pharmacokinetics in subjects with mild and moderate hepatic impairment. Presented at: 41st interscience, Conference on Antimicrobial Agents and Chemotherapy, 2001. Washington, DC. Abstract A34.
51. Uzun O, Kocagöz S, Cetinkaya Y, Arikan S, Unal S. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother. 1997:41:1156-1157.
52. Vazquez JA, Lynch M, Boikov D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother. 1997;41:1612-1614.
53. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005;27:657-673.
54. Vazquez JA. Anidulafungin: a novel echinocandin. Therapy. 2006a;3:39-54.
55. Vazquez JA. The safety of anidulafungin. Expert Opin Drug Saf.. 2006b;5:751-758.
56. Vazquez JA, Sobel JD, Anidulafungin: a novel echinacandin. Clin Infect Dis. 2006;43:215-222.
57. Vazquez JA, Schranz J, Clark K, Goldstein B, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. JAIDS. In press.
58. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004;190:1464-1471.
59. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs. 2003;12:1313-1333.
60. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
61. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-1239.
62. Zhanel GG, Karlowsky JA, Harding GA, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatiticis, and Aspergillus species. Antimicrob Agents Chemother. 1997;41:863-865.